Tvardi Therapeutics, Inc. (TVRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.74M
Last updated: Nov 17, 2026 at 11:04 AM ET
Tvardi Therapeutics, Inc. (TVRD) Stock Forecast
Analysts expect Tvardi Therapeutics (TVRD) to earn -$2.23 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 5 | 55.6% |
| Hold | 1 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 11.1% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$2.23
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.18
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.23 | -$3.02 to -$1.60 | 9 |
| Dec 31, 2027 | -$2.18 | -$4.52 to -$0.51 | 9 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.43 | -$0.83 to -$0.14 | 11 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.34.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.23 | -$2.23 | -$2.30 | -$2.35 | -$2.34 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.18 | -$2.18 | -$2.24 | -$2.37 | -$2.73 | N/A |
Frequently Asked Questions About TVRD
What is the TVRD stock forecast?
Consensus analyst estimates put Tvardi Therapeutics's EPS at -$2.23 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.
How do analysts rate TVRD stock?
Of 9 analysts covering Tvardi Therapeutics, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TVRD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.23, with estimates from -$3.02 to -$1.60 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.18, with estimates from -$4.52 to -$0.51 from 9 analysts.
How many analysts cover TVRD?
9 analysts rate Tvardi Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TVRD pages: Overview, Earnings, Forecast, Financials, Competitors